inclusion criteria: 1. age from 18 to 65 years of age, inclusive, at the time of signing the informed consent. 2. willing and able to provide informed consent. 3. women of reproductive potential must be using a highly effective method of contraception for at least 28 days prior to enrolment and must be able and willing to continue its use throughout the duration of the study. 4. men must agree to use condoms when engaging in heterosexual sex during the study and for the period up to 91 days after the last dose of study medication. men who are not randomized to a treatment arm including favipiravir (or another arm identified as having teratogenic potential through semen) will no longer need to adhere to this after randomization. 5. laboratory confirmed sars-cov-2 infection, and any of the following self-reported symptoms within 72 hours prior to randomization: fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia. 6. body weight ≥45 kg. 7. access to reliable video conference, telephone, direct/text messaging, or other device permitting real-time, reliable information transfer.

inclusion criteria: 1. age from 18 to 65 years of age, inclusive, at the time of signing the informed consent. 2. willing and able to provide informed consent. 3. women of reproductive potential must be using a highly effective method of contraception for at least 28 days prior to enrolment and must be able and willing to continue its use throughout the duration of the study. 4. men must agree to use condoms when engaging in heterosexual sex during the study and for the period up to 91 days after the last dose of study medication. men who are not randomized to a treatment arm including favipiravir (or another arm identified as having teratogenic potential through semen) will no longer need to adhere to this after randomization. 5. laboratory confirmed sars-cov-2 infection, and any of the following self-reported symptoms within 72 hours prior to randomization: fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia. 6. body weight ≥45 kg. 7. access to reliable video conference, telephone, direct/text messaging, or other device permitting real-time, reliable information transfer.

inclusion criteria: age from 18 to 65 years of age, inclusive, at the time of signing the informed consent. willing and able to provide informed consent. women of reproductive potential must be using a highly effective method of contraception for at least 28 days prior to enrolment and must be able and willing to continue its use throughout the duration of the study. men must agree to use condoms when engaging in heterosexual sex during the study and for the period up to 91 days after the last dose of study medication. men who are not randomized to a treatment arm including favipiravir (or another arm identified as having teratogenic potential through semen) will no longer need to adhere to this after randomization. laboratory confirmed sars-cov-2 infection, and any of the following self-reported symptoms within 72 hours prior to randomization: fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia. body weight ≥45 kg. access to reliable video conference, telephone, direct/text messaging, or other device permitting real-time, reliable information transfer.

inclusion criteria: age from 18 to 65 years of age, inclusive, at the time of signing the informed consent. willing and able to provide informed consent. women of reproductive potential must be using a highly effective method of contraception for at least 28 days prior to enrolment and must be able and willing to continue its use throughout the duration of the study. men must agree to use condoms when engaging in heterosexual sex during the study and for the period up to 91 days after the last dose of study medication. men who are not randomized to a treatment arm including favipiravir (or another arm identified as having teratogenic potential through semen) will no longer need to adhere to this after randomization. laboratory confirmed sars-cov-2 infection, and any of the following self-reported symptoms within 72 hours prior to randomization: fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia. body weight ≥45 kg. access to reliable video conference, telephone, direct/text messaging, or other device permitting real-time, reliable information transfer.

inclusion criteria: 1. age from 18 to 65 years of age, inclusive, at the time of signing the informed consent. 2. willing and able to provide informed consent. 3. women of reproductive potential must be using a highly effective method of contraception for at least 28 days prior to enrolment and must be able and willing to continue its use throughout the duration of the study. 4. men must agree to use condoms when engaging in heterosexual sex during the study and for the period up to 91 days after the last dose of study medication. men who are not randomized to a treatment arm including favipiravir (or another arm identified as having teratogenic potential through semen) will no longer need to adhere to this after randomization. 5. laboratory confirmed sars-cov-2 infection, and any of the following self-reported symptoms within 72 hours prior to randomization: fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia. 6. body weight ≥45 kg. 7. access to reliable video conference, telephone, direct/text messaging, or other device permitting real-time, reliable information transfer.

inclusion criteria: 1. age from 18 to 65 years of age, inclusive, at the time of signing the informed consent. 2. willing and able to provide informed consent. 3. women of reproductive potential must be using a highly effective method of contraception for at least 28 days prior to enrolment and must be able and willing to continue its use throughout the duration of the study. 4. men must agree to use condoms when engaging in heterosexual sex during the study and for the period up to 91 days after the last dose of study medication. men who are not randomized to a treatment arm including favipiravir (or another arm identified as having teratogenic potential through semen) will no longer need to adhere to this after randomization. 5. laboratory confirmed sars-cov-2 infection, and any of the following self-reported symptoms within 72 hours prior to randomization: fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia. 6. body weight ≥45 kg. 7. access to reliable video conference, telephone, direct/text messaging, or other device permitting real-time, reliable information transfer.